BMC Pulmonary Medicine is calling for submissions to our Collection on Cancer and the lung. Lung cancer remains one of the most prevalent forms of cancer worldwide, presenting unique challenges in both diagnosis and treatment. The complexity of lung cancer is exacerbated by the interplay between pulmonary conditions and various risk factors, including smoking, environmental exposures, and genetic predispositions. With advances in research, there is a growing understanding of the molecular mechanisms intertwined with lung cancer development and progression. The need for innovative approaches to diagnosis and treatment, as well as effective management strategies for patients, is more critical than ever in the fight against this devastating disease.

Research in the field of lung cancer has witnessed significant progress, particularly with the advent of targeted therapies and immunotherapies that have transformed treatment paradigms. As we gain more insight into the biology of lung cancer, we are better equipped to tailor therapeutic strategies that not only improve survival rates but also enhance the quality of life for patients. Understanding the role of lung cancer in the context of immunosuppression and infection opens new avenues for enhancing patient outcomes, especially in those with comorbidities. Potential research topics can include but are not limited to:

Mechanisms of lung cancer development

Innovations in lung cancer diagnosis

Immunotherapy and lung cancer treatments

Impact of lung infections in cancer patients

Chemotherapy and its effects on lung health

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating respiratory condition characterized by airflow limitation, primarily resulting from long-term exposure to harmful substances such as tobacco smoke and environmental pollutants. It encompasses two main conditions: emphysema and chronic bronchitis. Despite its prevalence and the significant burden it imposes on patients and healthcare systems worldwide, COPD remains underdiagnosed and undertreated. Research efforts have focused on understanding the pathophysiology of COPD, identifying risk factors, and developing effective management strategies, making this a critical area of investigation for researchers and clinicians alike.

Addressing COPD is paramount due to its increasing incidence and impact on quality of life for millions of individuals. Recent advances in diagnosis, including imaging techniques and biomarker identification, have enhanced our ability to identify and monitor the disease. Additionally, new treatment modalities, such as targeted therapies and personalized management approaches, have shown promise in improving patient outcomes. As we strive to better understand the complexities of COPD, ongoing research will play a pivotal role in reducing complications and co-morbidities associated with this condition, such as lung cancer and heart disease.

Continued research in this area may lead to breakthroughs in novel therapeutic approaches, including combination therapies that target multiple pathways involved in the disease process. Furthermore, as we gain deeper insights into the mechanisms of COPD, there is potential for the development of preventative strategies that could reduce the onset and progression of this chronic disease, ultimately enhancing patient quality of life and reducing healthcare costs.

Advances in COPD diagnosis

New treatments for COPD

Management strategies and quality of life

Comorbidities associated with COPD

Impact of COPD on lung cancer and heart disease

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.